Open AccessLong-term protection against dengue viruses in mice conferred by a tetravalent DNA vaccine candidate
Author(s) -
Ran Wang,
Fujia Yang,
Xiaoyan Zheng,
Xianzheng Liao,
Dongying Fan,
Hui Chen,
Jing An
Publication year - 2020
Publication title -
zoological research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.933
H-Index - 19
ISSN - 2095-8137
DOI - 10.24272/j.issn.2095-8137.2020.016
Subject(s) - dengue fever , heterologous , virology , immunity , dna vaccination , immunization , biology , dengue vaccine , antigen , immune system , antibody , dengue virus , immunology , genetics , gene
The development of an effective tetravalent vaccine against dengue viruses (DENVs) has become a world priority. We previously showed that four monovalent dengue DNA vaccines expressing premembrane (prM) and envelope (E) proteins displayed effective protection against corresponding challenges in mice. Thus, to elucidate the overall immunity and persistence of the tetravalent formulation (TetraME), we evaluated the humoral and cellular immune responses as well as the long-term protection in the current study. TetraME-immunized mice displayed increased production of Th1/Th2-typed cytokines upon stimulation with heterologous DENV antigens. Moreover, high levels of tetravalent DENV antibodies and sterilized immunity were detected long-term (30 weeks after immunization). These findings provide feasible validation for the potential utility of this vaccine formulation.